3rd Quarter - Report

MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY for MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY

Firm
Client
Income
—
Expenses
$202,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Proposals to repeal LIFO

LobbyistCovered position, as disclosed
JOSEPH M GANLEY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

Incentive for health information technology, Affordable Care Act, proposed regulation of medical software, proposals to promote healthcare interoperability, and other healthcare policy issues. H.R. 6, 21st Century Cures Act; H.R. 2396, SOFTWARE Act, S. 1101, MEDTECH Act.

LobbyistCovered position, as disclosed
JOSEPH M GANLEY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2396 (114th), S. 1101 (114th), H.R. 6 (114th)

Veterans VET

Existing Department of Veterans' Affairs Pharmaceutical Prime Vendor Contract

LobbyistCovered position, as disclosed
JOSEPH M GANLEY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

Physician and pharmacy reimbursement issues and implementation of the Affordable Care Act. H.R. 696 To amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare H.R. 2 Medicare Access and CHIP Reauthorization Act of 2015 H.R. 1416 Cancer Patient Protection Act of 2015 H.R. 2895, the Medicare Patient Access to Cancer Treatment Act

LobbyistCovered position, as disclosed
MATT BROW —
JOSEPH M GANLEY —
BEN JONES New —
KEAGAN R LENIHAN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 696 (114th), H.R. 2895 (114th), H.R. 1416 (114th), H.R. 2 (114th)

Pharmacy PHA

Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion, H.R. 471 "Ensuring Patient Access and Effective Drug Enforcement Act of 2015", S. 483 "Ensuring Patient Access and Effective Drug Enforcement Act of 2015"

LobbyistCovered position, as disclosed
JOSEPH M GANLEY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 483 (114th), H.R. 471 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.